Skip to main content

LL-37 (Cathelicidin) vs Epitalon

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

LL-37 (Cathelicidin)

LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.

Full details →

Epitalon

Epitalon (Epithalon) is a synthetic tetrapeptide based on the natural peptide epithalamin, produced by the pineal gland. It is primarily studied for its effects on telomerase activation.

Full details →

Side-by-Side Comparison

AspectLL-37 (Cathelicidin)Epitalon
MechanismDisrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects.Stimulates telomerase production, which can lengthen telomeres on DNA strands. May also regulate melatonin production and circadian rhythms.
Typical DosageResearch protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections.Typical protocols: 5-10mg daily for 10-20 days, repeated 2-3 times per year.
AdministrationSubcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols.Subcutaneous or intramuscular injection. Usually administered in cycles rather than continuously.
Side EffectsInjection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses.Generally well-tolerated. May affect sleep patterns initially.
Best For

Key Differences

Unique to LL-37 (Cathelicidin):

Unique to Epitalon:

Detailed Analysis

Epitalon and LL-37 (Cathelicidin) are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Epitalon for Sleep Quality. Choose LL-37 (Cathelicidin) for Recovery & Healing.

Ready to Learn More?